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บทคดัยอ่  
วตัถปุระสงค:์ เพือ่หาคา่พารามเิตอรท์างเภสชัจลนศาสตรข์องวอรโิคนาโซลซึง่จะ
น าไปสู่ขนาดวอริโคนาโซลที่เหมาะสมโดยแบ่งตามฟีโนไทป์ของ CYP2C19 
เพือ่ใหไ้ดร้ะดบัยาต ่าสุดในเลอืดอยูใ่นช่วงการรกัษาที ่1-5 มก./ลติร วิธีการศึกษา: 
การวจิยัเชงิส ารวจโดยการเก็บขอ้มูลยอ้นหลงัจากเวชระเบยีนของผูป้วยผูใ้หญ่ที่
ไดร้บัการรกัษาดว้ยวอรโิคนาโซลระหวา่งเดอืนมกราคม 2555 ถงึมนีาคม 2559 ณ 
โ ร งพย าบ าล ร าม าธิบ ดี  ข้ อ มู ล ดัง ก ล่ า ว  ไ ด้ แ ก่  อ ายุ  เ พ ศ  น ้ า หนั ก  
จโีนไทป์และฟีโนไทป์ของ CYP2C19 แบบแผนการใหย้าวอรโิคนาโซลและระดบั
ยาต ่าสุดในเลอืด แลว้ค านวณค่าพารามเิตอร์ทางเภสชัจลนศาสตร์ของวอรโิคนา
โซลโดยใช้สมการ Michaelis-Menten จากนัน้ค านวณขนาดวอรโิคนาโซลเพื่อให้
ระดบัยาอยู่ในช่วงการรกัษาแบ่งตามฟีโนไทป์ของ 2C19 ผลการศึกษา:จาก
ผูป่้วยทัง้หมด 53 ราย เป็นเพศชาย 29 ราย (54.7%) อายุและน ้าหนกัเฉลีย่ 52.98 
ปี และ 57.97 กโิลกรมั ตามล าดบั คา่มธัยฐานของคา่คงที ่Michaelis-Menten (Km) 
ส าหรับผู้ที่มีฟีโนไทป์ของ CYP2C19 แบบ extensive metabolizer (EM) และ 
แบบ non-extensive metabolizer (non-EM) เท่ากบั 0.262 มก./ลติร และ 0.666 
มก./ลติร ตามล าดบั (P-value = 0.008) ค่ามธัยฐานของอตัราการเมทาบอลสิมยา
สูงสุด (Vmax) ส าหรบั EM และ non-EM เท่ากบั 0.425 มก./กก./ชม. และ 0.483 
มก./กก./ชม. ตามล าดบั (P-value = 0.262) ขนาดวอรโิคนาโซลทีแ่นะน าเพือ่ใหไ้ด้
ระดบัยาต ่าสุดในเลอืดอยู่ในช่วง 1 - 5 มก./ลติร เท่ากบั 8.9 - 10.7 มก./กก./วนั 
และ 6.7 - 9.9 มก./กก./วัน ส าหรับ EM และ non-EM ตามล าดับ และเพื่อให้
สะดวกในทางปฏิบัติ ขนาดวอริโคนาโซลที่แนะน าส าหรบั EM และ non-EM 
เท่ากบั 10 มก./กก./วนั และ 8.5 มก./กก./วนั ตามล าดบั เพื่อใหไ้ดร้ะดบัยาต ่าสุด
ในเลอืดประมาณ 2 มก./ลติร สรปุ: การศกึษานี้ใหข้อ้มูล Km,Vmax และขนาดยาว
อรโิคนาโซลส าหรบัผูป่้วยผูใ้หญ่ไทยแบ่งตามฟีโนไทป์ของ CYP2C19 แต่จากคา่ 
Km และ Vmax ทีม่คีวามแปรปรวนค่อนขา้งมากพจิารณาจากช่วงทีก่วา้ง จงึยงัไม่
แนะน าให้ใช้ขนาดยาที่ค านวณได้จากการศึกษานี้จนกว่าจะได้ทดสอบความ
เหมาะสมของขนาดยาดงักลา่ว การตดิตามตรวจวดัระดบัยาในเลอืดจงึยงัจ าเป็น  
ค าส าคญั: วอรโิคนาโซล, ฟีโนไทป์ของ CYP2C19, เภสชัจลนศาสตร์แบบไม่เป็น
เสน้ตรง, ขนาดยาแนะน า 
  
 
 
Abstract 
Objective: To determine pharmacokinetic parameters of voriconazole (VRZ) 
that will lead to finding appropriate VRZ dose to maintain trough 
concentration (Ctr) within target therapeutic range of 1-5 mg/L based on 
CYP2C19 phenotype. Methods: The medical records of adult patients who 
received VRZ treatment between January 2012 and March 2016 at 
Ramathibodi Hospital were retrospectively reviewed. Patient’s data including 
gender, age, body weight, CYP2C19 genotype and phenotype, VRZ dosing 
regimen, and VRZ Ctr were collected. The pharmacokinetic parameters of 
VRZ were calculated using conventional nonlinear pharmacokinetic study, 
i.e., Michaelis-Menten equation. Proper dose for keeping VRZ Ctr within 
therapeutic range were then determined for each CYP2C19 phenotype. 
Results: A total of 53 patients were included into this study. Twenty-nine 
(54.7%) were male with mean age and body weight of 52.98 yrs and 57.97 
kg, respectively. Median Michaelis-Menten constant (Km) for CYP2C19 
extensive metabolizers (EM) and non-extensive metabolizers (non-EM) were 
0.262 mg/L and 0.666 mg/L, respectively (P-value = 0.008). Median 
maximum rate of metabolism (Vmax) for EM and non-EM were 0.425 mg/kg/h 
and 0.483 mg/kg/h, respectively (P-value = 0.262). The doses to achieve 
therapeutic Ctr (1 - 5 mg/L) were 8.9 - 10.7 mg/kg/day and 6.7 - 9.9 mg/kg/day 
for EM and non-EM, respectively. For more applicable in real world practice, 
the rounded dose of 10 mg/kg/day and 8.5 mg/kg/day for EM and non-EM, 
respectively, were recommended to provide VRZ Ctr around 2 mg/L. 
Conclusion: This present study provided Michaelis-Menten constant (Km and 
Vmax) of VRZ for Thai adult patients and the dose recommendation for this 
patient group based on CYP2C19 phenotype. The Km and Vmax of VRZ in 
this study show high variability judged from their wide range, therefore our 
recommended doses still cannot be used in practice unless its appropriate 
would be validated. Therapeutic drug monitoring of VRZ is still warranted.  
Keywords: voriconazole, CYP2C19 phenotype, nonlinear pharmacokinetic, 
dose recommendation 
 
 
Introduction 
Voriconazole (VRZ) is a synthetic triazole antifungal 
derived from fluconazole. VRZ has a broad spectrum and is 
recommended in the treatment of invasive fungal infections 
(IFIs) caused by common pathogens such as Aspergillus, 
Candida, Cryptococcus neoformans, as well as less common 
pathogens such as Fusarium and Pseudallescheria.1 IFIs 
caused by these species resulted in significant mortality and 
morbidity, especially in immunocompromised patients such as 
Editorial note 
Manuscript received in original form on January 10, 2018;  
revised December 5, 2019;  
and accepted in final form on December 18, 2019 Journal website: http://ejournals.swu.ac.th/index.php/pharm/index  
ไทยเภสชัศาสตรแ์ละวทิยาการสขุภาพ ปี 15 ฉบับ 1, มค. – มคี. 2563  44 Thai Pharm Health Sci J Vol. 15 No. 1, Jan. – Mar. 2020 
those receiving chemotherapy and immunosuppressive 
therapy (e.g., solid organ or bone marrow transplant patients, 
and systemic lupus erythematous (SLE) patients), or those 
infected with human immunodeficiency virus (HIV).2 VRZ 
pharmacokinetics exhibit high inter- and intra-individual 
variability because it has nonlinear pharmacokinetics 
associated with its saturated hepatic metabolism and with 
diverse patient characteristics. VRZ is metabolized mainly by 
CYP2C19 isozyme, and to the lesser extent by CYP3A4 and 
CYP2C9.3,4 Therefore, CYP2C19 polymorphisms may explain 
inter-individual variability in voriconazole exposure.4 
CYP2C19*2 and CYP2C19*3 are the variant alleles 
associated with a decreased activity of CYP2C19; on the 
contrary, CYP2C19*17 is the variant allele associated with an 
increased activity of CYP2C19.5,6 On the basis of CYP2C19 
metabolizing activity, individuals could be classified into four 
CYP2C19 phenotypes, specifically (i) ultra-rapid metabolizers 
(UM), e.g., *17/*17, *1/*17, (ii) extensive metabolizers (EM), 
e.g., *1/*1, (iii) intermediate metabolizers (IM), e.g., *1/*2, 
*1/*3, *2/*17, *3/*17, and (iv) poor metabolizers (PM), e.g., 
*2/*2, *3/*3, *2/*3.7 Many studies have shown that the 
frequency of CYP2C19 polymorphisms varies among different 
ethnic groups.8,9 A number of studies have documented that 
patients with a PM phenotype have VRZ plasma 
concentrations 2 - 4 times higher than those with an EM 
phenotype; while patients with a UM phenotype (*1/ *17, 
*17/*17) have voriconazole plasma levels lower than EM 
(*1/*1) patients.9-11 In addition to CYP2C19 polymorphism, 
various factors have been reported to influence the VRZ 
plasma concentrations such as age3,12, drug interactions3,12, 
albumin level13, C-reactive protein level13 and body weight3; 
whereas some studies reported no significant relationship 
between the plasma concentration and genotype14, age14, 
sex12,14 or use of concomitant proton pump inhibitors.14,15 
Unpredictability of VRZ plasma concentrations complicated its 
usefulness in clinical practice. This study aimed to determine 
pharmacokinetic parameters of VRZ based on CYP2C19 
phenotype which will lead to finding a dose that will optimize 
the invasive aspergillosis treatment.   
  
Methods 
         
Patient enrollment and data collection  
Thai patients aged 18 years or older who were being 
treated with voriconazole at least two different doses and had 
at least one plasma trough concentration (Ctr) of each dose at 
Ramathibodi Hospital, Thailand between January 2013 and 
March 2016 were eligible for participation. Patients’ medical 
records were reviewed and patients-specific characteristics 
were retrospectively collected. Voriconazole dosage regimen, 
administration time, blood sampling time, steady state 
voriconazole trough concentration, and duration of 
voriconazole treatment were collected. VRZ was considered 
to be at steady state after 24 hrs of administration following 
two loading doses or after 5 days without loading dose and 
blood samples were drawn before the next dose would be 
considered a trough concentration.16 Patients were excluded 
if they had severe hepatic disease which was defined as the 
Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0 of grade ≥ 4, or were pregnant. Voriconazole 
concentrations were analyzed by toxicology laboratory of 
Ramathibodi Hospital, Thailand where validated liquid 
chromatography mass spectrometry (LC-MS/MS) assay was 
used.  
 
DNA extraction and CYP2C19 genotyping  
Genomic DNA was extracted from venous blood 
specimens with the use of a purifier kit (QIAamp DNA Blood 
mini kit; Qiagen NV, Venlo, Netherlands) according to the 
manufacturer’s instructions. The association of genetic 
variants in the CYP2C19 gene encoding enzyme was tested 
in this study to assess the effect of CYP2C19*2 (splicing 
defect G681A SNP), CYP2C19*3 (stop codon G636A SNP) 
and CYP2C19*17 (increased enzyme activity g.−806 C > T) 
allelic variation in response to clopidogrel. A microarray-based 
technique (AmpliChip CYP450 test; Roche, Basel, 
Switzerland) was performed to genotype the CYP2C19 gene 
(*1/*2/*3). Regarding the predicted metabolic phenotypes 
related to CYP2C19 polymorphisms, an extensive metabolizer 
was defined as a patient who had a homozygous wild-type 
genotype (CYP2C19*1/*1) and an ultra-rapid metabolizer was 
defined as a patient who had a heterozygous genotype with 
at least one CYP2C19*17 allele 
(CYP2C19*1/*17 or CYP2C19*17/*17). An intermediate 
metabolizer was defined as a patient who had a heterozygous 
genotype with at least one 
CYP2C19*1 allele (CYP2C19*1/*2 or *1/*3), and a poor 
metabolizer was classified as a patient who had a 
homozygous (CYP2C19*2/*2 or *3/*3) or heterozygous (CYP 
2C19*2/*3) genotype with a mutant allele.   
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This study was performed in accordance with the 
Declaration of Helsinki, 1996 good clinical practice. The study 
protocol was approved by the Ethics Committee of 
Ramathibodi Hospital, Thailand (Protocol number 07-57-21).  
 
Analysis of voriconazole pharmacokinetics 
Voriconazole exhibits nonlinear pharmacokinetic profiles 
which could be described by Michaelis-Menten equation (1)  
   
𝑅    =     
 𝑉𝑚𝑎𝑥 . 𝐶
𝐾𝑚 + 𝐶
                                                          (1) 
  
R specifies a voriconazole dosing rate which is expressed 
in milligram per kilogram per hour (mg/kg/h). With an initial 
dosing rate of 8 mg/kg/day, dosing rate would be adjusted 
according to the measured concentration. Vmax represents the 
maximum rate of metabolism at saturating substrate 
concentration (mg/kg/h). Km or Michaelis constant is 
voriconazole concentration at which the metabolism rate is 
half of Vmax which is expressed in milligram per liter (mg/L). 
Finally, C is the steady state voriconazole trough 
concentration (mg/L). To determine patient-specific 
pharmacokinetic parameters, Km and Vmax, we need two 
dosing rates (R1 and R2) and one trough concentration from 
each dosing rate (C1 and C2) using the equations (2) and (3). 
Then the recommended dose will be calculated (R) using 
previously determined Km and Vmax for this patient group to 
keep voriconazole concentration within therapeutic range (i.e., 
1.0 - 5.0 mg/L).   
 
𝐾𝑚     =       
𝑅1 − 𝑅2
𝑅2
𝐶2
−
𝑅1
𝐶1
                                                  (2) 
   
𝑉𝑚𝑎𝑥     =     𝐾𝑚
𝑅
𝐶
+ 𝑅                                             (3) 
   
Statistical analysis  
Statistical analysis was performed using SPSS, version 21 
(SPSS Inc., Chicago, IL, USA). Continuous data (i.e., Km and 
Vmax) were presented as mean with standard deviation and 
median with interquartile range (IQR); while categorical data 
as proportions. Analyses of continuous data were performed 
using Mann-Whitney U test due to the nonnormality of 
voriconazole concentrations. Statistical significance was set at 
a type I error of 5%, or P-value of less than 0.05.  
 
 
   
Results 
    
Subjects and clinical characteristics  
A total of 53 adult patients with invasive aspergillosis (IA) 
who were receiving voriconazole and whose submitted blood 
samples were analyzed for voriconazole trough plasma 
concentrations were included in this study. Demographic and 
clinical characteristics of the patient population are 
summarized in Table 1. Mean (SD) age of patients in this 
study was 52.98 (15.64) years.  Slightly more than half (n = 
29, or 54.7%) of the patients were male. Mean (SD) body 
weight is 57.97 (9.99) kg.  
The number and frequencies of variant alleles of 
CYP2C19 in our population are shown in Table 1.  Of these 
patients, *1/*1 was the majority (n = 26, or 49.1%) followed by 
*1/*2 (n = 19, or 35.8%).  When patients were classified 
according to CYP2C19 phenotypes, there were 26 (49.1%) 
extensive metabolizers (EM), 22 (41.5%) intermediate 
metabolizers (IM), and 5 (9.4%) poor metabolizers (PM).  
  
Pharmacokinetic analysis  
Median (IQR) Km of VRZ was 0.262 (0.29) mg/L for EM 
and 0.666 (1.78) mg/L for non-EM (P-value = 0.008). Median 
(IQR) Vmax of VRZ was 0.425 (0.14) mg/kg/h and 0.483 (0.25) 
mg/kg/h for EM and non-EM, respectively. Median (IQR) 
plasma VRZ trough concentration (Ctr) after initiation of same 
maintenance dose of 8 mg/kg/day, divided into 2 doses, were 
1.870 mg/L (3.20) and 2.060 mg/L (4.69), for EM and non-EM, 
respectively (Table2). No significant differences were 
observed for Vmax and Ctr between CYP2C19 EM and non-
EM.  
 
 Table 1  Demographic and clinical characteristics of 
participants (N = 53).  
Characteristics Number of patients (%) 
Gender  
Male  29 (54.7) 
Female  24 (45.3) 
Age (yrs), mean  SD (range) 52.98  15.64 (18.09 - 82.48) 
Body weight (kg), mean  SD (range) 57.97  9.99 (38.80 - 84.00) 
CYP2C19 genotype    
 *1/*1 26 (49.1) 
 *1/*2 19 (35.8) 
 *1/*3 3 (5.7) 
 *2/*2 2 (3.8) 
 *3/*3 1 (1.9) 
 *2/*3 2 (3.8) 
CYP2C19 phenotype   
 Extemsive metabolizer (EM) 26 (49.1) 
 Non-EM  
 Intermediate metabolizer 22 (41.5) 
 Poor metabolizer 5 (9.4) 
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 Table 2  Pharmacokinetic parameters of voriconazole 
classified by CYP2C19 phenotype (N = 53).  
CYP2C19 
phenotype 
median ± IQR 
Km (mg/L) P-value Vmax (mg/kg/h) P-value Ctrough (mg/L) P-value 
EM (n = 26) 0.262 ± 0.29 
0.008** 
0.425 ± 0.14 
0.262 
1.870 ± 3.20 
0.845 
Non-EM (n = 27) 0.666 ± 1.78 0.483 ± 0.25 2.060 ± 4.69 
* Statistically significant at P-value < 0.01, Median Km and Vmax for all patients were 0.391 mg/L and 0.467 mg/kg/h, respectively.  
 
Based on calculated pharmacokinetics parameters, 
median Km of 0.262 mg/L for EM and 0.666 mg/L for non-EM, 
and median Vmax of 0.467 mg/kg/h for all patients, optimal 
dose of VRZ were then be estimated using Michaelis-Menten 
equation (eq.1) to keep Ctr within a therapeutic range of 1.0 - 
5.0 mg/L. The recommend doses were 8.9 – 10.7 mg/kg/day 
and 6.7 – 9.9 mg/kg/day divided into 2 equal doses and given 
every 12 hrs, for EM and non-EM, respectively (Table 3).  
To be more applicable in clinical practice, we recommend 
VRZ daily dose of 10 mg/kg/day and 8.5 mg/kg/day for EM 
and non-EM, respectively, to keep plasma VRZ Ctrough 
approximately 2 mg/L. 
 
 Table 3  Recommended VRZ dose for IA treatment 
according to CYP2C19 phenotype (N = 53).  
Target Trough  
Concentration (mg/L) 
Dose (mg/kg/day)  
Extensive metabolizer 
(N = 26) 
Non-extensive metabolizer 
(N = 27) 
1 8.9 6.7 
1.5 9.5 7.8 
2 9.9 8.4 
2.5 10.2 8.9 
3 10.3 9.2 
3.5 10.4 9.4 
4 10.5 9.6 
4.5 10.6 9.8 
5 10.7 9.9 
Recommended dose* (mg/kg/day) 10.0 8.5 
 * To keep Ctr of approximately 2 mg/L.  
 
Discussions and Conclusion 
Calculated Km for EM was lower than that in non-EM which 
was reasonable because the lower Km the higher metabolizing 
activity. The median Km for all of our patients was 0.391 mg/L 
which was lower than Km reported by Masumoto K et al. of 
1.32 mg/L.17 It was possibly since there was a higher 
frequency of CYP2C19 EM in our study when compared to 
that frequency reported in Japanese population.7 Other factor 
that might explain the low value of our patient’s Km was there 
was no CYP2C19*17 genotype which is a functioning allele, 
in our study. However, the frequency of this variant in Thai 
population was relatively low. Other than CYP2C19, CYP3A4 
is also responsible for VRZ metabolism and CYP3A4 is a 
polymorphism as well; but the effects of CYP3A4 variants 
were not examined in this study. Regarding calculated Vmax, it 
was not much different between the value of our patients and 
previous studies4,17,18, that means the maximum rate of VRZ 
metabolism was not different among ethnic groups.  
Conventional pharmacokinetic study can be used even in 
the setting that CYP2C19 genotyping was not available, dose 
adjustment can be performed by Km and Vmax calculation. 
Nonetheless, population pharmacokinetic was also be 
performed and reported in our other study (unpublished data). 
Doses recommended by the present study was not equal 
to those in VRZ package insert which recommend daily dose 
of 12 mg/kg/day, divided into 2 equal doses for 1 day as 
loading dose followed by 8 mg/kg/day given every 12 hrs as 
maintenance doses for adult patient.19 Based on our 
calculation, if EM individuals received VRZ dose as 
recommended in the package insert, VRZ plasma Ctr will lower 
than 1 mg/L which was insufficient while those with IM or PM 
can maintain VRZ plasma Ctr within therapeutic range. 
CYP2C19 EM was the majority of Thai population as well as 
Asian population. Therefore, CYP2C19 polymorphisms should 
get more attention for VRZ dosing to optimize VRZ plasma 
Ctr. Based on our calculation, we recommend a maintenance 
dose of 10 mg/kg/day for CYP2C19 EM and 8.5 mg/kg/day for 
non-EM to maintain the steady state VRZ Ctr around 2 mg/L.   
It can be seen that the calculated Km and Vmax value had 
a high uncertainty, considering a fairly wide range compared 
to the median value. Alhough the median Ctr levels after 
receiving the same maintenance dose were not different 
between EM and non-EM, these values were presented with 
wide ranges. However, they showed the reasonably trend of 
a higher median Ctr for non-EM. Acoordingly, the 
recommended dose in this study is still not recommended for 
practical use, unless its propriety would be validated because 
of the high inter-individual variation. 
Our study had several limitations. This retrospective study 
enrolled a relatively small number of patients with a limited 
number of PMs (9.4%, 5/53). We did not exclude patients who 
received medications that may interact with voriconazole. 
Most frequently co-administered VRZ with possible drug 
interactions were proton pump inhibitors and glucocorticoids. 
The study of Zvyaga et al. revealed that proton pump inhibitors 
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are mostly weak inhibitors of cytochrome P450 in vivo; 
however, two members (esomeprazole and omeprazole) are 
more likely to serve as clinically relevant inhibitors of 
CYP2C19.20 Nonetheless, another study showed that 
receiving proton pump inhibitors together with VRZ had no 
effect on VRZ levels and only patients who received higher 
dose of omeprazole (> 20 mg/d) were more likely to have 
higher concentrations of VRZ.15 In addition, there was a study 
showing that omeprazole was the most potent CYP2C19 
inhibitor, whereas rabeprazole had no influence on VRZ 
(omeprazole > esomeprazole > lansoprazole > rabeprazole). 
However, in consideration of the therapeutic concentration 
range, dosage adjustment of VRZ is unnecessary regardless 
of which proton pump inhibitor was co-administered.21  There 
were three patients in this present study receiving omeprazole 
before initiating VRZ but had been changed to lansoprazole 
once VRZ was introduced.  
When considering the induction of CYP2C19, there were 
no co-administrations of VRZ and CYP2C19 inducers, such 
as rifampicin, phenobarbital, phenytoin, or carbamazepine. 
However, co-administration of glucocorticoids was found. 
Glucocorticoids may increase or decrease VRZ level via 
CYP3A4 and CYP2C19 interactions.22 Recent study reported 
an inverse correlation between VRZ concentration and 
corticosteroid dose.23 The results from a systematic review by 
Li et al. showed that glucocorticoids had inconclusive effect 
on VRZ pharmacokinetics.24 From six cohorts, one showed 
that treatment with glucocorticoids had no impact on VRZ Ctr, 
three studies reported that glucocorticoids slightly elevated the 
metabolism of VRZ but with no significance, and it did not 
affect the plasma exposure of VRZ. Two studies included in 
the review found that co-administration of VRZ with 
glucocorticoids led to a significant decrease in normalized 
VRZ Ctr.24 However, one recent physiology-based 
pharmacokinetic model study showed that the predicted 
maximum concentration and the area under the plasma 
concentration-time curve from 0 hrs to infinity (AUC0→inf) of 
VRZ remained unchanged when in combination with 
dexamethasone.25 It suggested that dexamethasone had no 
influence on the pharmacokinetics of VRZ.25  
In addition, results from a population pharmacokinetic 
analysis showed that both proton pump inhibitors and 
glucocorticoids were not a significant covariate of VRZ 
clearance.26 In our present study, many patients were on 
glucocorticoids and proton pump inhibitors concomitantly.Co-
administration of a CYP450 enzyme inducer and inhibitor 
simultaneously could potentially decrease the potential effects 
of these medications. However, physicians should continue to 
pay attention when prescribing enzyme inducers and inhibitors 
together with voriconazole.  
Furthermore, since there were only five PMs included in 
this study, we could not calculate the recommended dose for 
each phenotypic group, i.e. EM, IM, and PM. The study of Kim 
et al. could offer CYP2C19 phenotype-guided initial dosing 
regimen for EM, IM, and PM individuals.26 Unfortunately, 
optimal recommendation corresponding to individual 
phenotype differences could be made but with some cautions. 
Therefore, further studies with a relatively large number of 
patients with each CYP2C19 phenotype are needed.  
In conclusion, Km and Vmax of VRZ in EM and non-EM 
were 0.262 mg/L and 0.425 mg/kg/h, and 0.666 mg/L and 
0.483 mg/kg/h, respectively. Our recommended maintenance 
dose of VRZ directed by CYP2C19 phenotype of 10 
mg/kg/day and 8.5 mg/kg/day for CYP2C19 EM and non-EM 
have not been validated, therefore it is not recommended for 
practical use. In addition, we recommended therapeutic drug 
monitoring should be performed concurrently with VRZ 
treatment due to high intra- and inter-individual variation of 
VRZ’s pharmacokinetics.   
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